# Eric H Raabe

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 97 papers | 3,089 citations | 186265 28 h-index | 168389 53 g-index |
| 100 all docs | 100 docs citations | 100 times ranked | 5336 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559. | 30.7 | 473 |
| 2 | Disrupting the CD47-SIRPÎ± anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Science Translational Medicine, 2017, 9, . | 12.4 | 306 |
| 3 | Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell, 2020, 183, 1962-1985.e31. | 28.9 | 177 |
| 4 | BRAF Activation Induces Transformation and Then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model. Clinical Cancer Research, 2011, 17, 3590-3599. | 7.0 | 167 |
| 5 | Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. Genes and Development, 2004, 18, 1035-1046. | 5.9 | 163 |
| 6 | Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Science Translational Medicine, 2019, 11, . | 12.4 | 129 |
| 7 | The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature Communications, 2019, 10, 2235. | 12.8 | 96 |
| 8 | Management of Pediatric and Adult Patients with Medulloblastoma. Current Treatment Options in Oncology, 2014, 15, 581-594. | 3.0 | 82 |
| 9 | Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget, 2015, 6, 3165-3177. | 1.8 | 66 |
| 10 | LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget, 2013, 4, 1050-1064. | 1.8 | 63 |
| 11 | Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro-Oncology, 2013, 15, 1604-1614. | 1.2 | 62 |
| 12 | Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition. Journal of Neuropathology and Experimental Neurology, 2015, 74, 778-790. | 1.7 | 61 |
| 13 | ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres. Brain Pathology, 2015, 25, 724-732. | 4.1 | 59 |
| 14 | Morphologic Characteristics and Immunohistochemical Profile of Diffuse Intrinsic Pontine Gliomas. American Journal of Surgical Pathology, 2013, 37, 1357-1364. | 3.7 | 55 |
| 15 | DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clinical Cancer Research, 2016, 22, 3903-3914. | 7.0 | 54 |
| 16 | The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Letters, 2017, 400, 110-116. | 7.2 | 52 |
| 17 | The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Letters, 2016, 377, 55-64. | 7.2 | 50 |
| 18 | ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. PLoS ONE, 2018, 13, e0204159. | 2.5 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Translational Oncology, 2019, 12, 1314-1322. | 3.7 | 46 |
| 20 | PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget, 2018, 9, 19177-19191. | 1.8 | 45 |
| 21 | Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332. | 7.0 | 44 |
| 22 | Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. Pediatric Blood and Cancer, 2008, 51, 10-16. | 1.5 | 37 |
| 23 | Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathologica Communications, 2014, 2, 59. | 5.2 | 35 |
| 24 | Alterations in cellular metabolome after pharmacological inhibition of <scp>N</scp>otch in glioblastoma cells. International Journal of Cancer, 2016, 138, 1246-1255. | 5.1 | 32 |
| 25 | New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model. Clinical Cancer Research, 2013, 19, 4553-4558. | 7.0 | 31 |
| 26 | Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. Translational Oncology, 2019, 12, 96-105. | 3.7 | 31 |
| 27 | MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657. | 7.0 | 30 |
| 28 | An immunocompetent mouse model of human glioblastoma. Oncotarget, 2017, 8, 61072-61082. | 1.8 | 30 |
| 29 | The Chromatin-Modifying Protein HMGA2 Promotes Atypical Teratoid/Rhabdoid Cell Tumorigenicity. Journal of Neuropathology and Experimental Neurology, 2015, 74, 177-185. | 1.7 | 26 |
| 30 | Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. Journal of Pediatric Hematology/Oncology, 2016, 38, 249-260. | 0.6 | 26 |
| 31 | An SNF2 factor involved in mammalian development and cellular proliferation. Developmental Dynamics, 2001, 221, 92-105. | 1.8 | 25 |
| 32 | The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas. Neuro-Oncology, 2017, 19, 1068-1078. | 1.2 | 25 |
| 33 | Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity. Neuro-Oncology, 2020, 22, 563-574. | 1.2 | 24 |
| 34 | The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas. Neuro-Oncology, 2021, 23, 572-585. | 1.2 | 23 |
| 35 | Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Clinical Cancer Research, 2019, 25, 5925-5936. | 7.0 | 22 |
| 36 | Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro-Oncology, 2019, 21, 252-263. | 1.2 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. Neuro-Oncology, 2021, 23, 770-782. | 1.2 | 18 |
| 38 | The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro-Oncology, 2017, 19, 1361-1371. | 1.2 | 17 |
| 39 | The therapeutic and diagnostic potential of regulatory noncoding RNAs in medulloblastoma. Neuro-Oncology Advances, 2019, 1, vdz023. | 0.7 | 16 |
| 40 | Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis. Journal of Neuropathology and Experimental Neurology, 2021, 80, 336-344. | 1.7 | 16 |
| 41 | Differential laminin isoform expression in the developing rat olfactory system. Developmental Brain Research, 1997, 101, 187-196. | 1.7 | 15 |
| 42 | Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. Oncotarget, 2018, 9, 8054-8067. | 1.8 | 15 |
| 43 | Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clinical Cancer Research, 2021, 27, 1807-1820. | 7.0 | 12 |
| 44 | Diffusion tensor imaging suggests extrapontine extension of pediatric diffuse intrinsic pontine gliomas. European Journal of Radiology, 2016, 85, 700-706. | 2.6 | 10 |
| 45 | PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. Journal of Neuropathology and Experimental Neurology, 2020, 79, 74-85. | 1.7 | 10 |
| 46 | Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways. Cancers, 2022, 14, 1311. | 3.7 | 10 |
| 47 | Methylome Alterations â€œMarkâ€•New Therapeutic Opportunities in Glioblastoma. Cancer Cell, 2012, 22, 417-418. | 16.8 | 9 |
| 48 | A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica, 2013, 126, 607-608. | 7.7 | 9 |
| 49 | mTOR: a new therapeutic target for pediatric low-grade glioma?. CNS Oncology, 2014, 3, 89-91. | 3.0 | 8 |
| 50 | Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for highâ€MYC medulloblastoma. Neuropathology, 2019, 39, 71-77. | 1.2 | 8 |
| 51 | Non-adhesive and highly stable biodegradable nanoparticles that provide widespread and safe transgene expression in orthotopic brain tumors. Drug Delivery and Translational Research, 2020, 10, 572-581. | 5.8 | 7 |
| 52 | Notch Signaling Activation in Pediatric Low-Grade Astrocytoma. Journal of Neuropathology and Experimental Neurology, 2015, 74, 121-131. | 1.7 | 6 |
| 53 | Lessons From Pediatric HIV: A Case for Curative Intent in Pediatric Cancer in LMICs. Pediatrics, 2017, 140, e20170525. | 2.1 | 6 |
| 54 | Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc. Current Signal Transduction Therapy, 2013, 8, 55-66. | 0.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Letters, 2021, 504, 137-145. | 7.2 | 5 |
| 56 | Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant Glioma. Molecular and Cellular Proteomics, 2021, 20, 100123. | 3.8 | 5 |
| 57 | MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. Journal of Neuropathology and Experimental Neurology, 2020, 79, 746-753. | 1.7 | 4 |
| 58 | Treatment of Hepatoblastoma With Drug-eluting Bead Transarterial Chemoembolization in a 13-Month-Old Infant: A Case Report and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2021, 43, e123-e126. | 0.6 | 4 |
| 59 | Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. Cell Death and Disease, 2022, 13, 410. | 6.3 | 4 |
| 60 | Highâ€risk medulloblastoma: Does câ€myc amplification overrule histopathology?. Pediatric Blood and Cancer, 2010, 54, 344-345. | 1.5 | 3 |
| 61 | Subtotal Splenic Embolization is a Safe and Effective Treatment for Isolated Splenic Vascular Tumors Associated With Consumptive Coagulopathy. Journal of Pediatric Hematology/Oncology, 2011, 33, 383-386. | 0.6 | 3 |
| 62 | BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2015, 17, iii3-iii3. | 1.2 | 2 |
| 63 | HIGHLY SELECTIVE INTRA-ARTERIAL CHEMOTHERAPY FOR THE TREATMENT OF PROGRESSIVE DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). Neuro-Oncology, 2014, 16, iii29-iii29. | 1.2 | 1 |
| 64 | DIPG-34. A HUMAN NEURAL STEM CELL DIPG MODEL IDENTIFIES THE RELATIVE CONTRIBUTION OF DIFFERENT ONCOGENIC ELEMENTS TO INVASIVE MALIGNANT TRANSFORMATION. Neuro-Oncology, 2018, 20, i55-i56. | 1.2 | 1 |
| 65 | OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage. Neuro-Oncology Advances, 2021, 3, ii15-ii15. | 0.7 | 1 |
| 66 | EXTH-15. MULTI-FACETED INHIBITION OF TET PATHWAY WITH CELL-PERMEABLE 2HG AND BOBCAT 339 REDUCES PROLIFERATION AND INDUCES APOPTOSIS IN DIPG. Neuro-Oncology, 2021, 23, vi166-vi166. | 1.2 | 1 |
| 67 | CSIG-32. microRNA 211, A POTENTIAL THERAPEUTIC AGENT FOR GROUP 3 MEDULLOBLASTOMA IN CHILDREN. Neuro-Oncology, 2021, 23, vi40-vi40. | 1.2 | 1 |
| 68 | MB-27 * PATHWAY ANALYSIS OF A HUMAN NEURAL STEM CELL MODEL OF AGGRESSIVE MEDULLOBLASTOMA REVEALS CKD INBHIBITION AS A POTENTIAL THERAPEUTIC MODALITY. Neuro-Oncology, 2015, 17, iii25-iii26. | 1.2 | 0 |
| 69 | PDTB-11. DISRUPTING THE EPIGENETIC MODIFIER HMGA2 IN LETHAL PEDIATRIC AND ADULT GLIOMAS INHIBITS INVASION, GROWTH AND TUMORIGENICITY. Neuro-Oncology, 2016, 18, vi152-vi152. | 1.2 | 0 |
| 70 | MB-103DiSCoVERing INNOVATIVE THERAPIES: COMBINING GENETICALLY ACCURATE DISEASE MODELS OF MEDULLOBLASTOMA WITH ADVANCED IN SILICO ANALYSIS TO IDENTIFY NOVEL THERAPEUTIC TARGETS. Neuro-Oncology, 2016, 18, iii120.3-iii120. | 1.2 | 0 |
| 71 | LGG-13. SYNERGISTIC TREATMENT FOR PEDIATRIC LOW GRADE GLIOMA WITH THE DUAL MTORC1/2 INHIBITOR TAK-228 AND MEK INHIBITOR TRAMETINIB. Neuro-Oncology, 2017, 19, iv35-iv36. | 1.2 | 0 |
| 72 | DIPG-61. HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT SYNERGIZES WITH DUAL MTOR INHIBITOR TAK228 TO POTENTIATE KILLING OF DIPG CELLS. Neuro-Oncology, 2018, 20, i61-i61. | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | MBRS-61. IN VIVO METABOLOMICS REVEALS A POTENT COMBINATION THERAPY FOR MYC-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i141-i141. | 1.2 | 0 |
| 74 | ATRT-37. TARGETING ATYPICAL TERATOID/RHABDOID TUMOR USING MATURE LET-7 LEADS TO INCREASED APOPTOSIS. Neuro-Oncology, 2018, 20, i35-i36. | 1.2 | 0 |
| 75 | DIPG-75. INTERSECTION OF EPIGENETICS AND IMMUNITY IN DIPG. Neuro-Oncology, 2018, 20, i64-i64. | 1.2 | 0 |
| 76 | LGG-52. DUAL INHIBITION OF mTORC1/C2 AND MEK PATHWAY IS SYNERGISTIC IN MULTIPLE HUMAN MODELS OF PEDIATRIC LOW-GRADE GLIOMA INCLUDING A NOVEL PATIENT-DERIVED NF1 PILOCYTIC ASTROCYTOMA CELL LINE. Neuro-Oncology, 2018, 20, i115-i116. | 1.2 | 0 |
| 77 | MBRS-30. TORC1/2 INHIBITION SENSITIZES MYC-DRIVEN MEDULLOBLASTOMA CELLS TO CARBOPLATIN CHEMOTHERAPY. Neuro-Oncology, 2018, 20, i134-i135. | 1.2 | 0 |
| 78 | DIPG-62. CARBOPLATIN SYNERGIZES WITH BCL-2 INHIBITOR TO POTENTIATE KILLING OF DIPG CELLS. Neuro-Oncology, 2018, 20, i61-i61. | 1.2 | 0 |
| 79 | DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i49-i50. | 1.2 | 0 |
| 80 | DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES. Neuro-Oncology, 2018, 20, i49-i49. | 1.2 | 0 |
| 81 | ATRT-04. UNBIASED METABOLIC PROFILING OF ATYPICAL TERATOID/RHABDOID TUMORS PREDICTS SENSITIVITY TO GLUTAMINE METABOLIC INHIBITORS. Neuro-Oncology, 2019, 21, ii63-ii63. | 1.2 | 0 |
| 82 | PDTM-18. COMBINED SUPPRESSION OF THE mTOR AND MAPK PATHWAYS INHIBITS GROWTH, DECREASES VASCULARITY AND INDUCES APOPTOSIS OR SENESCENCE IN PEDIATRIC LOW GRADE GLIOMA. Neuro-Oncology, 2019, 21, vi191-vi191. | 1.2 | 0 |
| 83 | GENE-09. LONG NONCODING RNA lncHLX2-7 A PUTATIVE MOLECULAR MARKER AND A THERAPEUTIC TARGET FOR GROUP III MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, vi99-vi99. | 1.2 | 0 |
| 84 | Psychosis Remitted After Ependymoma Resection in a School-Aged Child. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 305-308. | 1.8 | 0 |
| 85 | ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328. | 1.2 | 0 |
| 86 | Response to letter to the editor: â€œAll models are wrong; some models are usefulâ€• Neuro-Oncology, 2020, 22, 1406-1407. | 1.2 | 0 |
| 87 | FSMP-18. COMPREHENSIVE METABOLIC PROFILING OF HIGH MYC MEDULLOBLASTOMA REVEALS KEY DIFFERENCES BETWEEN IN VITRO AND IN VIVO GLUCOSE AND GLUTAMINE USAGE. Neuro-Oncology Advances, 2021, 3, i19-i19. | 0.7 | 0 |
| 88 | BCOR Internal Tandem Duplication Expression in Neural Stem Cells Promotes Growth, Invasion, and Expression of PRC2 Targets. International Journal of Molecular Sciences, 2021, 22, 3913. | 4.1 | 0 |
| 89 | HGG-30. BRAIN PENETRANT HDAC INHIBITOR RG2833 SYNERGIZES WITH LOMUSTINE AND RADIATION TO INDUCE DIPG CELL DEATH. Neuro-Oncology, 2021, 23, i23-i23. | 1.2 | 0 |
| 90 | Abstract 324: Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600Emutant glioma. , 2021, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | DIPG-12. TARGETING EPIGENETIC MODIFIERS TO INDUCE IMMUNE SIGNALING IN DIPG. Neuro-Oncology, 2020, 22, iii289-iii289. | 1.2 | 0 |
| 92 | DIPG-62. Reducing the levels of genomic 5-hydroxymethylcytosine by inhibiting the TET pathway induces apoptosis and decreases proliferation in Diffuse Intrinsic Pontine Glioma (DIPG). Neuro-Oncology, 2022, 24, i33-i33. | 1.2 | 0 |
| 93 | DIPG-52. Activators of the integrated stress response synergize to kill DIPG. Neuro-Oncology, 2022, 24, i30-i30. | 1.2 | 0 |
| 94 | MODL-17. The Childhood Brain Cancer Cell Line Atlas: A Resource for Biomarker Identification and Therapeutic Development. Neuro-Oncology, 2022, 24, i172-i172. | 1.2 | 0 |
| 95 | DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG. Neuro-Oncology, 2022, 24, i29-i30. | 1.2 | 0 |
| 96 | MEDB-02. The identification and functional characterization of circular RNA Circ_63706 in sonic hedgehog medulloblastomas. Neuro-Oncology, 2022, 24, i103-i103. | 1.2 | 0 |
| 97 | Abstract 3987: Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death. Cancer Research, 2022, 82, 3987-3987. | 0.9 | 0 |